Tags

Type your tag names separated by a space and hit enter

Neutralizing and binding activities against SARS-CoV-1/2, MERS-CoV, and human coronaviruses 229E and OC43 by normal human intravenous immunoglobulin derived from healthy donors in Japan.
Transfusion. 2021 02; 61(2):356-360.T

Abstract

BACKGROUND

There are several types of coronaviruses that infect humans and cause disease. The latest is severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which is an emerging global threat with no current effective treatment. Normal intravenous immunoglobulin (N-IVIG) has been administered to coronavirus disease 2019 (COVID-19) patients to control severe inflammation and the cellular immune response. However, the neutralizing activity of N-IVIG against SARS-CoV-2 has not yet been fully evaluated. The aim of this study was to determine whether N-IVIG manufactured before the start of the COVID-19 pandemic contained IgG antibodies against the circulating human coronaviruses (HCoVs) that cross-react with the highly pathogenic coronaviruses SARS-CoV-1, Middle East respiratory syndrome coronavirus (MERS-CoV), and SARS-CoV-2. No cases of SARS-CoV-1 or MERS-CoV have been reported in Japan.

STUDY DESIGN AND METHODS

The neutralizing and binding activities of N-IVIG against SARS-CoV-1, MERS-CoV, SARS-CoV-2, HCoV 229E, and HCoV OC43 were evaluated. Nine N-IVIG lots manufactured between 2000 and 2018, derived from donors in Japan, were tested. Binding activity was evaluated by indirect immunofluorescence assay.

RESULTS

None of the N-IVIG lots tested displayed neutralizing or binding activity against SARS-CoV-1, MERS-CoV, or SARS-CoV-2. However, they displayed substantial neutralizing and binding activity against HCoV OC43 and weak neutralizing and substantial binding activity against HCoV 229E.

CONCLUSION

N-IVIG derived from healthy donors in Japan before the start of the COVID-19 pandemic had no direct effect against SARS-CoV-2. Further studies are warranted to determine the effects of N-IVIG manufactured after the start of the COVID-19 pandemic against SARS-CoV-2.

Authors+Show Affiliations

Department of Viral Infections, Research Institute for Microbial Diseases, Osaka University, Suita, Japan.Laboratory of Clinical Research on Infectious Diseases, Research Institute for Microbial Diseases, Osaka University, Suita, Japan.Research and Development Division, Japan Blood Products Organization, Tokyo, Japan.Department of Viral Infections, Research Institute for Microbial Diseases, Osaka University, Suita, Japan.Department of Viral Infections, Research Institute for Microbial Diseases, Osaka University, Suita, Japan.Laboratory of Clinical Research on Infectious Diseases, Research Institute for Microbial Diseases, Osaka University, Suita, Japan. Department of Infectious Diseases and Host Defense, Graduate School of Medicine, Gunma University, Maebashi, Japan.Department of Viral Infections, Research Institute for Microbial Diseases, Osaka University, Suita, Japan.

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

33104267

Citation

Kubota-Koketsu, Ritsuko, et al. "Neutralizing and Binding Activities Against SARS-CoV-1/2, MERS-CoV, and Human Coronaviruses 229E and OC43 By Normal Human Intravenous Immunoglobulin Derived From Healthy Donors in Japan." Transfusion, vol. 61, no. 2, 2021, pp. 356-360.
Kubota-Koketsu R, Terada Y, Yunoki M, et al. Neutralizing and binding activities against SARS-CoV-1/2, MERS-CoV, and human coronaviruses 229E and OC43 by normal human intravenous immunoglobulin derived from healthy donors in Japan. Transfusion. 2021;61(2):356-360.
Kubota-Koketsu, R., Terada, Y., Yunoki, M., Sasaki, T., Nakayama, E. E., Kamitani, W., & Shioda, T. (2021). Neutralizing and binding activities against SARS-CoV-1/2, MERS-CoV, and human coronaviruses 229E and OC43 by normal human intravenous immunoglobulin derived from healthy donors in Japan. Transfusion, 61(2), 356-360. https://doi.org/10.1111/trf.16161
Kubota-Koketsu R, et al. Neutralizing and Binding Activities Against SARS-CoV-1/2, MERS-CoV, and Human Coronaviruses 229E and OC43 By Normal Human Intravenous Immunoglobulin Derived From Healthy Donors in Japan. Transfusion. 2021;61(2):356-360. PubMed PMID: 33104267.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Neutralizing and binding activities against SARS-CoV-1/2, MERS-CoV, and human coronaviruses 229E and OC43 by normal human intravenous immunoglobulin derived from healthy donors in Japan. AU - Kubota-Koketsu,Ritsuko, AU - Terada,Yutaka, AU - Yunoki,Mikihiro, AU - Sasaki,Tadahiro, AU - Nakayama,Emi E, AU - Kamitani,Wataru, AU - Shioda,Tatsuo, Y1 - 2020/10/26/ PY - 2020/07/27/received PY - 2020/09/06/revised PY - 2020/09/18/accepted PY - 2020/10/27/pubmed PY - 2021/3/6/medline PY - 2020/10/26/entrez KW - COVID-19 KW - IVIG KW - MERS KW - SARS KW - binding KW - coronavirus KW - neutralization SP - 356 EP - 360 JF - Transfusion JO - Transfusion VL - 61 IS - 2 N2 - BACKGROUND: There are several types of coronaviruses that infect humans and cause disease. The latest is severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which is an emerging global threat with no current effective treatment. Normal intravenous immunoglobulin (N-IVIG) has been administered to coronavirus disease 2019 (COVID-19) patients to control severe inflammation and the cellular immune response. However, the neutralizing activity of N-IVIG against SARS-CoV-2 has not yet been fully evaluated. The aim of this study was to determine whether N-IVIG manufactured before the start of the COVID-19 pandemic contained IgG antibodies against the circulating human coronaviruses (HCoVs) that cross-react with the highly pathogenic coronaviruses SARS-CoV-1, Middle East respiratory syndrome coronavirus (MERS-CoV), and SARS-CoV-2. No cases of SARS-CoV-1 or MERS-CoV have been reported in Japan. STUDY DESIGN AND METHODS: The neutralizing and binding activities of N-IVIG against SARS-CoV-1, MERS-CoV, SARS-CoV-2, HCoV 229E, and HCoV OC43 were evaluated. Nine N-IVIG lots manufactured between 2000 and 2018, derived from donors in Japan, were tested. Binding activity was evaluated by indirect immunofluorescence assay. RESULTS: None of the N-IVIG lots tested displayed neutralizing or binding activity against SARS-CoV-1, MERS-CoV, or SARS-CoV-2. However, they displayed substantial neutralizing and binding activity against HCoV OC43 and weak neutralizing and substantial binding activity against HCoV 229E. CONCLUSION: N-IVIG derived from healthy donors in Japan before the start of the COVID-19 pandemic had no direct effect against SARS-CoV-2. Further studies are warranted to determine the effects of N-IVIG manufactured after the start of the COVID-19 pandemic against SARS-CoV-2. SN - 1537-2995 UR - https://www.unboundmedicine.com/medline/citation/33104267/Neutralizing_and_binding_activities_against_SARS_CoV_1/2_MERS_CoV_and_human_coronaviruses_229E_and_OC43_by_normal_human_intravenous_immunoglobulin_derived_from_healthy_donors_in_Japan_ L2 - https://doi.org/10.1111/trf.16161 DB - PRIME DP - Unbound Medicine ER -